lapatinib has been researched along with Astrocytoma, Grade IV in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A | 1 |
| Haeno, H; Michor, F; Stein, S; Vivanco, I; Zhao, R | 1 |
| Akhavan, D; Babic, I; Bensinger, SJ; Cavenee, WK; Cloughesy, TF; Dang, J; Flagg, M; James, CD; Kornblum, HI; Mischel, PS; Nael, A; Nathanson, D; Nourian, AA; Pourzia, AL; Sasayama, T; Tamanoi, F; Tanaka, K; Villa, GR; Vinters, HV; Williams, KJ; Yang, H; Yong, WH | 1 |
| Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Tavallai, S | 1 |
| Brown, D; Butowski, N; Cheng, SY; Giles, FJ; James, CD; Mazar, AP; Nicolaides, T; Ozawa, T; Parsa, AT; Raizer, JJ; Sarkaria, JN; Shen, W; Stegh, AH; Yao, TW; Yoshida, Y | 1 |
| Dermawan, JK; Gurova, KV; Hitomi, M; Lathia, JD; Purmal, AA; Rich, JN; Sandlesh, P; Silver, DJ; Sloan, AE; Stark, GR; Venere, M; Wu, Q | 1 |
| Battastini, AM; Coelho, BP; de Quadros, AH; Gaelzer, MM; Gonçalves, CA; Guerra, MC; Guma, FC; Hoppe, JB; Salbego, CG; Setton-Avruj, P; Terra, SR; Usach, V | 1 |
| Belanger, K; Easaw, J; Eisenhauer, E; Forsyth, P; Kamel-Reid, S; Mason, W; McIntosh, L; Schaiquevich, P; Stewart, C; Thiessen, B; Tsao, M | 1 |
| Akhavan, D; Bensinger, SJ; Cloughesy, TF; Dang, J; DeAngelis, LM; Guo, D; Hock, MB; Horvath, S; Huang, TT; Iwanami, A; Kofman, AA; Kuga, D; Kuhn, JG; Lin, KY; Mehta, MP; Mellinghoff, IK; Mischel, PS; Prados, MD; Prins, RM; Robins, HI; Soto, H; Vinters, HV; Watson, AD; Wen, PY; Yong, WH; Zhu, S | 1 |
| Argyriou, AA; Dimitropoulos, K; Giannopoulou, E; Kalofonos, HP; Petsas, T; Tsiata, E; Zolota, V | 1 |
| Akhavan, D; Amzajerdi, AN; Babic, I; Chakravarti, A; Cloughesy, TF; Dang, J; Deangelis, LM; Dejesus, J; Gini, B; Guo, D; Hong, C; Huang, TT; Iwanami, A; James, CD; Kuga, D; Lisiero, DD; Mehta, MP; Mellinghoff, IK; Mischel, PS; Nathanson, D; Prados, MD; Prins, RM; Reinitz, F; Robins, HI; Soto, H; Tanaka, K; Tontonoz, P; Wen, PY; Youssef, M; Zhu, S | 1 |
3 trial(s) available for lapatinib and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Karnofsky Performance Status; Lapatinib; Male; Middle Aged; Necrosis; Pilot Projects; Quinazolines; Temozolomide; Thrombocytopenia; Treatment Outcome | 2017 |
De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
Topics: Adult; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Mice, SCID; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain Neoplasms; Cytochrome P-450 CYP3A; Enzyme Induction; ErbB Receptors; Female; Glioblastoma; Humans; Lapatinib; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Polymorphism, Single Nucleotide; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2 | 2010 |
8 other study(ies) available for lapatinib and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Computational Biology; Drug Administration Schedule; ErbB Receptors; Glioblastoma; Humans; Lapatinib; Logistic Models; Maximum Tolerated Dose; Models, Biological; Mutation; Protein Kinase Inhibitors; Quinazolines | 2018 |
Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.
Topics: Anoikis; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; bcl-X Protein; Beclin-1; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 9; Cell Line, Tumor; Drug Synergism; ErbB Receptors; fas Receptor; Fas-Associated Death Domain Protein; Glioblastoma; Humans; Lapatinib; Lysosomal-Associated Membrane Protein 2; MAP Kinase Kinase 1; Membrane Proteins; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridines; Quinazolines; Sorafenib; TOR Serine-Threonine Kinases; Unfolded Protein Response | 2015 |
NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Expression; Glioblastoma; Humans; Lapatinib; Mice; Quinazolines; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models.
Topics: Animals; Brain Neoplasms; Carbazoles; DNA-Binding Proteins; Glioblastoma; High Mobility Group Proteins; Humans; Lapatinib; Mice; Quinazolines; Transcriptional Elongation Factors | 2016 |
Phosphatidylinositol 3-Kinase/AKT Pathway Inhibition by Doxazosin Promotes Glioblastoma Cells Death, Upregulation of p53 and Triggers Low Neurotoxicity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Chromones; Doxazosin; Enzyme Activation; G1 Phase Cell Cycle Checkpoints; Glioblastoma; Glycogen Synthase Kinase 3 beta; Hippocampus; Humans; Lapatinib; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Rats, Wistar; Tumor Suppressor Protein p53 | 2016 |
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.
Topics: Antineoplastic Agents; Brain Neoplasms; ErbB Receptors; Fatty Acids; Gene Knockdown Techniques; Glioblastoma; Humans; Hydrolysis; Lapatinib; Lipogenesis; Phosphatidylinositol 3-Kinases; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; Sterol Regulatory Element Binding Protein 1 | 2009 |
The effects of anti-VEGFR and anti-EGFR agents on glioma cell migration through implication of growth factors with integrins.
Topics: Cell Line, Tumor; Cell Movement; ErbB Receptors; Focal Adhesion Kinase 1; Glioblastoma; Humans; Indoles; Integrin beta1; Integrin beta3; Integrins; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib; Vascular Endothelial Growth Factor Receptor-1 | 2010 |
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Brain Neoplasms; Cell Death; Cholesterol; ErbB Receptors; Glioblastoma; HeLa Cells; Humans; Lapatinib; Liver X Receptors; Mice; Mice, SCID; Orphan Nuclear Receptors; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, LDL; Signal Transduction; Sterol Regulatory Element Binding Protein 1; Up-Regulation | 2011 |